fair-market value

3.6.2014 Clinical Development

Using Per-Patient Visit as Basis to Compensate Investigators

By Yanis Saradjian, Director of Consulting There is a strong push from regulators worldwide for pharmaceutical companies to first report and then justify physician payments. This push includes all compensation for activities such as scientific speaking,...
 

12.18.2013 Fair-Market Value

Watch Your Service Fees So That CMS Doesn’t Have To

By Jacob Presson, Research Analyst After the Sunshine Act was released and a Final Rule was issued in early 2013, pharmaceutical companies geared up to make sure that their reporting and disclosure systems were in good working order.  Determining...
 

11.21.2013

Setting Fair-Market Value Based on Salary? Try KOL Activity Instead

By Elio Evangelista, Director of Operations Having just completed a new benchmarking study on fair-market value (FMV) rates in the Middle East, Cutting Edge Information uncovered a few important trends that may also affect country-level teams in...
 

3.4.2013 Fair-Market Value

Transparency for FMV Rates: Finding a Balance Abroad

When France first released its 2011 draft of the Bertrand Act — which included a provision similar to the Sunshine Act here in the US – the legislation promised to be more stringent than US guidelines.  The draft required companies to post its payments on...
 

2.7.2013 KOL Management

The Sunshine Act is Ready — Is Pharma?

At last.  Cue the Etta James music because the Centers for Medicare and Medicaid Services (CMS) released the final version of the Sunshine Act.  As of February 8, the Sunshine Act will be included in the Federal Register and will go into effect shortly thereafter....
 

5.9.2012 IIT Studies

Four Guideposts to Improve Investigator-Initiated Trials Payment Processes for FMV Compliance

By David Richardson, Research Team Leader The Office of the Inspector General at Health and Human Services (OIG) has been highly focused recently on tracking and publicizing pharmaceutical companies' payments to thought leader physicians and clinical...
 

4.21.2012 KOL Management

Drug Companies Embrace Transparency in Physician Compensation

The wave of pharmaceutical transparency laws has not yet crested, according to research from Cutting Edge Information, and drug companies are responding with steps to reveal their compensation to physicians. Cutting Edge Information's recent study "Pharmaceutical...
 

4.12.2012 Fair-Market Value

Physician Payment Disclosures and FMV Going Strong Despite Sunshine Act Delays

By Elio Evangelista, Director of Research The United States is still waiting for the Centers for Medicare and Medicaid Services (CMS) to issue its final ruling on how it will implement the disclosure rules outlined in the Physician Payments Sunshine...
 

2.17.2012 Fair-Market Value

Fair-Market Value Benchmarking Service Provides KOL Compensation Data for More Than 100 Countries

By Yanis Saradjian,Director of Consulting Our newly updated Fair-Market Value Benchmarking and Analysis service now provides medical, scientific and regulatory staff at life sciences companies with fair-market value benchmarks for thought leaders and influential...
 

1.30.2012 Fair-Market Value

Extended Sunshine Act deadline provides extra time to track and report physician payments

Six Tips to Help Build the Ideal Thought Leader Database As the industry awaits the release of the delayed Sunshine Act guidelines, pharmaceutical and medical device companies are benefiting from the extra time by reviewing current physician payment reporting...